The recent media coverage of interim results from the PATHFINDER2 study of GRAIL's Galleri multicancer detection blood test exemplifies a troubling and recurring trend in science communication: the commercially driven, premature framing of non-peer-reviewed data as proof of a transformative breakthrough. Released via an embargoed press statement on Oct 17, 2025, and then presented as a late-breaking abstract at the…
[Comment] Media coverage and PATHFINDER2: hype, simplification, and free advertising
The Lancet Oncology | | Clare Turnbull, Anna Schuh, Richard Sullivan, Paul Pharoah, Matthew E J Callister, Ajay Aggarwal, Stuart Hogarth, Margaret McCartney, Richard Houlston
Topics: blood-cancer, research